MedWellAI Inc. (MWAI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MedWellAI Inc. (MWAI) trades at $0.35. MedWellAI Inc. operates in the financial services sector, focusing on AI-driven healthcare and wellness solutions. Market cap: $2.29M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for MWAI: MWAI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MWAI against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MWAI: 2/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →MedWellAI Inc. (MWAI) Financial Services Profile
MedWellAI Inc., formerly Integrated Ventures, provides AI-driven healthcare and wellness solutions, including a B2B e-commerce platform for pharmaceutical products and an AI-powered ordering system for healthcare providers. Operating in the financial services sector, the company aims to leverage AI to enhance healthcare delivery and pharmaceutical distribution.
What Is the Investment Thesis for MWAI?
MedWellAI Inc. presents a speculative investment opportunity given its focus on AI-driven healthcare solutions and its B2B e-commerce platform for pharmaceutical products. The company's high gross margin of 85.0% suggests potential for profitability if revenue scales significantly. However, the negative P/E ratio of -0.88 and a substantial negative profit margin of -441.2% indicate current financial challenges. The company's beta of 2.70 suggests high volatility relative to the market. Growth catalysts include the increasing adoption of AI in healthcare and the rising demand for GLP medications. The company's ability to secure partnerships with healthcare providers and expand its product offerings will be crucial for future growth. Investors should closely monitor the company's ability to improve its financial performance and achieve profitability. The pending AI analysis may provide further insights into the company's technological capabilities and market potential.
Based on FMP financials and quantitative analysis
MWAI Key Highlights
Gross Margin of 85.0% indicates strong potential for profitability if revenue scales effectively.
- Negative Profit Margin of -441.2% highlights significant financial challenges and the need for improved cost management.
- Beta of 2.70 suggests high volatility, indicating a higher risk investment.
- P/E Ratio of -0.88 reflects current losses and limited earnings.
- Focus on AI-driven healthcare solutions positions the company in a high-growth market segment.
Who Are MWAI's Competitors?
MWAI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FDCT FDCTech, Inc. | $3.08 | -11.75% | $13.0M | 61 |
| CBTTF Cathedra Bitcoin Inc. | $0.46 | +25.16% | $13.4M | 56 |
| BBKCF BIGG Digital Assets Inc. | $0.05 | -6.09% | $16.5M | 62 |
| GSIW Garden Stage Limited provides financial services in Hong Kong, including securities dealing and brokerage, underwriting and placing, and asset management. The company | $16.80 | -0.74% | $23.7M | 61 |
| PLUT Plutus Financial Group Limited | $2.64 | -2.94% | $40.5M | 53 |
| WDBG Woodbrook Group Holdings Inc. | $0.50 | +0.00% | 57 | |
| STGC StartEngine Crowdfunding, Inc. | $0.15 | -94.83% | $113M | 61 |
| GEVI General Enterprise Ventures, Inc. | $9.08 | +8.61% | $159M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MWAI's Key Strengths?
Focus on AI-driven healthcare solutions.
- B2B e-commerce platform for pharmaceutical products.
- High gross margin of 85.0%.
- AI-powered ordering system for healthcare providers.
What Are MWAI's Weaknesses?
Negative profit margin of -441.2%.
- Limited market capitalization.
- High beta of 2.70 indicating high volatility.
- Small number of employees.
What Could Drive MWAI Stock Higher?
Increasing adoption of AI in healthcare and wellness industries.
- Rising demand for GLP medications for weight loss and diabetes management.
- Potential partnerships with healthcare providers to expand market reach.
- Development of new AI-driven diagnostic tools for early disease detection.
- Geographic expansion into new markets to diversify revenue streams.
What Are the Key Risks for MWAI?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition in the healthcare technology sector.
- Regulatory challenges in the pharmaceutical industry.
- Economic downturn affecting healthcare spending.
- Technological obsolescence of AI-driven solutions.
- Limited financial disclosure and low trading volume due to OTC listing.
What Are the Growth Opportunities for MWAI?
- Expansion of B2B E-commerce Platform: MedWellAI can expand its B2B e-commerce platform to include a broader range of pharmaceutical products and healthcare supplies. The global pharmaceutical e-commerce market is projected to reach $200 billion by 2028, offering significant growth potential. By enhancing its platform with advanced features such as AI-driven inventory management and personalized recommendations, MedWellAI can attract more healthcare providers and increase its market share. Timeline: Ongoing.
- Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with wellness clinics, med spas, and corporate wellness facilities can drive adoption of MedWellAI's AI-powered ordering system. The market for healthcare IT solutions is expected to reach $400 billion by 2027. By offering customized solutions and integrated support, MedWellAI can establish long-term relationships with key healthcare providers. Timeline: Ongoing.
- Development of AI-Driven Diagnostic Tools: MedWellAI can leverage its AI capabilities to develop diagnostic tools for early detection of diseases and personalized treatment plans. By focusing on specific therapeutic areas such as diabetes and weight management, MedWellAI can create niche products that address unmet needs in the healthcare market. Timeline: Upcoming.
- Geographic Expansion into New Markets: MedWellAI can expand its operations into new geographic markets, both domestically and internationally. The global healthcare market is experiencing strong growth in emerging economies, driven by increasing healthcare spending and rising demand for advanced medical technologies. By adapting its products and services to local market needs, MedWellAI can tap into new revenue streams and diversify its customer base. Timeline: Upcoming.
- Integration of Telehealth Services: Integrating telehealth services into its platform can enhance MedWellAI's value proposition and attract more customers. The telehealth market is projected to reach $300 billion by 2028, driven by increasing adoption of remote patient monitoring and virtual consultations. By offering integrated telehealth solutions, MedWellAI can provide comprehensive healthcare services and improve patient outcomes. Timeline: Upcoming.
What Are MWAI's Competitive Advantages?
- Proprietary AI-powered ordering system.
- Established B2B e-commerce platform for pharmaceutical products.
- Focus on GLP medications for weight loss and diabetes management.
- Strategic partnerships with healthcare providers.
What Does MWAI Do?
MedWellAI Inc., formerly known as Integrated Ventures, Inc., underwent a strategic transformation in June 2025 to focus on AI-driven healthcare and wellness solutions. The company develops, acquires, operates, and invests in businesses within this evolving sector. Its core offerings include a B2B e-commerce platform designed for distributing pharmaceutical products, with a particular emphasis on GLP medications used for weight loss and diabetes management. This platform aims to streamline the procurement process for healthcare providers, ensuring efficient access to essential medications. In addition to its e-commerce platform, MedWellAI provides an AI-powered ordering system equipped with inventory tracking, smart suggestions, and comprehensive support for healthcare providers. This system caters to a diverse range of facilities, including wellness clinics, med spas, and corporate wellness facilities, enhancing their operational efficiency and patient care capabilities. Headquartered in Clearwater, Florida, MedWellAI is positioned to capitalize on the growing demand for AI-integrated solutions in the healthcare and wellness industries. The company's strategic focus on leveraging technology to improve healthcare delivery and pharmaceutical distribution underscores its commitment to innovation and market leadership.
What Products and Services Does MWAI Offer?
- Develops AI-driven healthcare and wellness solutions.
- Operates and invests in businesses within the healthcare sector.
- Provides a B2B e-commerce platform for pharmaceutical products.
- Offers GLP medications for weight loss and diabetes management.
- Provides an AI-powered ordering system with inventory tracking.
- Supports healthcare providers such as wellness clinics and med spas.
How Does MWAI Make Money?
- Generates revenue through the sale of pharmaceutical products on its B2B e-commerce platform.
- Provides AI-powered ordering systems to healthcare providers on a subscription basis.
- Acquires and invests in businesses within the healthcare and wellness sectors.
- Offers AI-driven healthcare and wellness solutions.
What Industry Does MWAI Operate In?
MedWellAI Inc. operates within the financial services sector, specifically targeting the intersection of healthcare and technology. The market for AI-driven healthcare solutions is experiencing rapid growth, driven by the need for improved efficiency, personalized care, and cost reduction. The competitive landscape includes established healthcare technology companies and emerging startups focused on AI applications in pharmaceuticals and healthcare delivery. MedWellAI's success depends on its ability to differentiate its offerings, secure strategic partnerships, and navigate the regulatory complexities of the healthcare industry.
Who Are MWAI's Key Customers?
- Wellness clinics
- Med spas
- Corporate wellness facilities
- Healthcare providers
Company Profile
MedWellAI Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Clearwater, US. The company is led by CEO Stanislav Rubakh. MWAI has traded publicly since 2017.
Financial Health
MedWellAI Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for MedWellAI Inc. stands at 59.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -45.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -170.8%, the inverse of the P/E and a quick read on earnings relative to price.
MWAI Valuation & Market Position
With a $2.29M market cap, MedWellAI Inc. sits in the micro-cap segment of the market.
Insider Activity
The most recent 11 insider filings for MedWellAI Inc. break down as 1 sales and 10 purchases. On net that is roughly 20K shares disposed (about $16K), a signal worth weighing alongside the fundamentals.
MWAI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on AI-driven healthcare solutions.
- B2B e-commerce platform for pharmaceutical products.
- High gross margin of 85.0%.
- AI-powered ordering system for healthcare providers.
Bear Case
- Negative profit margin of -441.2%.
- Limited market capitalization.
- High beta of 2.70 indicating high volatility.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
MWAI Latest News
No recent news available for MWAI.
MWAI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MWAI.
Price Targets
Wall Street price target analysis for MWAI.
MWAI MoonshotScore
What does this score mean?
The MoonshotScore rates MWAI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Stanislav Rubakh
CEO
Stanislav Rubakh is the CEO of MedWellAI Inc. His background includes experience in managing and developing businesses. He is responsible for the overall strategic direction and operational management of the company. With a focus on leveraging AI to enhance healthcare solutions, Rubakh aims to drive innovation and growth within the organization. His leadership is crucial in navigating the evolving landscape of the healthcare technology sector and ensuring the company's success.
Track Record: Under Stanislav Rubakh's leadership, MedWellAI Inc. has focused on developing AI-driven healthcare solutions and establishing a B2B e-commerce platform for pharmaceutical products. Key milestones include the company's name change in June 2025 to reflect its strategic focus on AI and the development of its AI-powered ordering system for healthcare providers. His strategic decisions are aimed at positioning the company as a leader in the healthcare technology market.
MWAI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MedWellAI Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and transparency compared to exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume can lead to price volatility and difficulty in executing trades.
- Higher potential for fraud and manipulation compared to listed exchanges.
- OTC Other tier companies may have limited operating history or unproven business models.
- Regulatory oversight is minimal, increasing the risk of non-compliance.
- Verify the company's registration and legal status with state and federal authorities.
- Review available financial statements and assess the company's financial health.
- Research the background and experience of the company's management team.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and potential trading risks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal disputes involving the company.
- Company's focus on AI-driven healthcare solutions aligns with current market trends.
- Development of a B2B e-commerce platform for pharmaceutical products.
- Name change to MedWellAI Inc. reflects a strategic shift towards AI.
- Company's headquarters are located in Clearwater, Florida.
- Focus on GLP medications for weight loss and diabetes management.
MWAI Financial Services Stock FAQ
What does MedWellAI Inc. do?
MedWellAI Inc. operates as a financial services company focused on developing, acquiring, and investing in businesses within the AI-driven healthcare and wellness sector. The company provides a B2B e-commerce platform for distributing pharmaceutical products, particularly GLP medications used for weight loss and diabetes management.
What do analysts say about MWAI stock?
Currently, there is no available analyst coverage for MWAI stock. Given the company's focus on AI-driven healthcare solutions and its B2B e-commerce platform, potential investors should closely monitor key valuation metrics such as revenue growth, gross margin, and profitability.
What are the main risks for MWAI?
MedWellAI Inc. faces several risks, including intense competition in the healthcare technology sector, regulatory challenges in the pharmaceutical industry, and the potential for technological obsolescence. The company's negative profit margin and limited market capitalization also pose financial risks. Additionally, as an OTC-listed company, MWAI faces risks associated with limited financial disclosure, low trading volume, and potential price volatility. Investors should carefully consider these risks before investing in MWAI.
What are the key factors to evaluate for MWAI?
Evaluate MWAI on fundamentals, analyst consensus, and risk factors. MedWellAI Inc. presents a speculative investment opportunity given its focus on AI-driven healthcare solutions and its B2B e-commerce platform for pharmaceutical products. Not financial advice.
How frequently does MWAI data refresh on this page?
MWAI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MWAI's recent stock price performance?
MedWellAI Inc. (MWAI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on AI-driven healthcare solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MWAI overvalued or undervalued right now?
MedWellAI Inc. (MWAI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MWAI before investing?
Before investing in MedWellAI Inc. (MWAI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully representative of the company's current performance.
- AI analysis is pending and may provide further insights into the company's technological capabilities.